Cleveland Clinic Journal of Medicine (CCJM)Lipoprotein(a) in Clinical Practice: What Clinicians Need to Know

Elevated lipoprotein(a) affects 20-25% of the global population as a genetic cardiovascular risk factor that standard lipid therapies fail to control. New RNA-based drugs achieving 80-100% reductions in phase 2 trials may finally provide treatment options by 2026.

⚖️ CLINICAL CONSIDERATIONS

• No consensus exists on universal screening—European/Canadian guidelines recommend testing all adults while US guidelines limit to high-risk patients only
• Levels fluctuate more than previously recognized, particularly with renal impairment, menopause, and inflammatory states—53% of intermediate-risk patients reclassify on retesting
• PCSK9 inhibitors reduce lipoprotein(a) 20-25% and show greater cardiovascular benefit in patients with baseline levels >120 nmol/L despite modest reductions
• Phase 3 trials for pelacarsen and olpasiran report 2026—both achieved near-universal reductions below treatment thresholds in phase 2 studies

🎯 PRACTICE APPLICATIONS

• Measure lipoprotein(a) at least once in patients with premature ASCVD or strong family history
• Target LDL-C <70 mg/dL or 50% reduction when lipoprotein(a) exceeds 125 nmol/L threshold
• Retest intermediate-risk patients (75-125 nmol/L) especially with renal disease or hormonal changes
• Refer to preventive cardiology for elevated lipoprotein(a) with recurrent events or trial access

More in Lipid Health